Dr. Eliaz is Founder and Managing Director at Elrom Ventures, where he also served as a Managing Director at aMoon Fund. Previously, Rom was Head of Merck ventures’ Fund and Bio-Incubator in Israel where he co-founded several companies in the incubator, VP of Innovative Branded Products at Teva and CEO of NasVax (TASE: NSVX) and Immcure Therapeutics.
Rom has a track record of steering companies to success, as VP of Development and Project Management at Intradigm (merged with Silence Therapeutics), VP of Product Development and Project Management at Rinat Neuroscience (acquired by Pfizer). Rom led several blockbuster drugs to market and advanced clinical trials while managing Johnson & Johnson’s investment portfolios following its acquisition of Alza.
Rom served as Assistant Professor at University of California San Francisco, published over 40 scientific articles and holds more than 10 scientific patents in the fields of drug targeting and delivery, gene therapy and tissue engineering.
Rom received his PhD (cum-laude) in chemical engineering and Biotechnology from the Weizmann Institute and Ben-Gurion (BGU). His summa cum laude BSc and MSc degrees in chemical engineering and Biotechnology are from BGU, and he holds an MBA (cum laude) from the Harvard Business School and Boston University joint program at BGU.
